Krieger T, Pearson I, Bell J, Doherty J, Robbins P. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. Diagn Pathol. 2020 Jan 30;15(1):6. doi: 10.1186/s13000-020-0927-9
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.
Palka P, Lange A, Wright RA, Starkey IR, Fleming AD, Bouki KP, Sutherland GR, Shaw TRD, Fox KAA. Myocardial velocity gradient measured throughout the cardiac cycle in dilated cardiomyopathy hearts — a potential new parameter of systolic and diastolic myocardial function by Doppler myocardial imaging. European journal of ultrasound. 1997 Jun 1;5(3):141-54. doi: 10.1016/S0929-8266(97)00014-1
Hoskins PR, Fleming A, Stonebridge PA, Allan PL, Cameron D. Scan-plane vector maps and secondary flow motions in arteries. European journal of ultrasound. 1994 Apr 1;1(2):159-69.